WO2007014150A3 - Method of administering liposomes containing oligonucleotides - Google Patents
Method of administering liposomes containing oligonucleotides Download PDFInfo
- Publication number
- WO2007014150A3 WO2007014150A3 PCT/US2006/028658 US2006028658W WO2007014150A3 WO 2007014150 A3 WO2007014150 A3 WO 2007014150A3 US 2006028658 W US2006028658 W US 2006028658W WO 2007014150 A3 WO2007014150 A3 WO 2007014150A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cationic
- liposomal composition
- bis
- effective amount
- cationic liposomal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Abstract
The invention provides a method of treating a cellular proliferative disease, a method of inhibiting the growth of neoplastic cells and a method of reducing the expression of a raf sequence by administering an effective amount of a cationic liposomal composition. The cationic liposomal composition comprises c-raf Antisense Oligonucleotide (c-rafAON), a cationic cardiolipin analogue and, desirably, another lipid species. The preferred cationic cardiolipin analogue is l,3-Bis-(l,2-bis-tetradecyloxy-propyl-3- dimethylethoxyammoniumbromide)-propane-2-ol (PCL-2). The preferred lipids include cholesterol, dioleoylphosphatidylethanolamine (DOPE), 1,2 Dioleoyl-sn-glycero-3- phosphocholine (DOPC), alpha tocopheryl acid succinate and phosphatidylcholine. The effective amount of the cationic liposomal composition is about 60 mg/m2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70177505P | 2005-07-22 | 2005-07-22 | |
US60/701,775 | 2005-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007014150A2 WO2007014150A2 (en) | 2007-02-01 |
WO2007014150A3 true WO2007014150A3 (en) | 2007-05-24 |
Family
ID=37683879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/028658 WO2007014150A2 (en) | 2005-07-22 | 2006-07-24 | Method of administering liposomes containing oligonucleotides |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007014150A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
US8367628B2 (en) | 2005-12-01 | 2013-02-05 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
WO2008103431A2 (en) * | 2007-02-23 | 2008-08-28 | Pronai Therapeutics, Inc. | Dnai - liposomes |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
WO1998043095A1 (en) * | 1997-03-21 | 1998-10-01 | Georgetown University | Liposomes containing oligonucleotides |
WO2004035523A1 (en) * | 2002-10-16 | 2004-04-29 | Neopharm, Inc. | Cationic cardiolipin analogs and use thereof |
-
2006
- 2006-07-24 WO PCT/US2006/028658 patent/WO2007014150A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
WO1998043095A1 (en) * | 1997-03-21 | 1998-10-01 | Georgetown University | Liposomes containing oligonucleotides |
US6126965A (en) * | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
WO2004035523A1 (en) * | 2002-10-16 | 2004-04-29 | Neopharm, Inc. | Cationic cardiolipin analogs and use thereof |
Non-Patent Citations (1)
Title |
---|
SIMONZADEH ET AL.: "Determination of cationic cardiolipin in liposomal formulations by a robust HPLC method", 227TH AMERICAN CHEMICAL SOCIETY NATIONAL MEETING, 28 March 2004 (2004-03-28) - 1 April 2004 (2004-04-01), pages ABSTR. NO. 148 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007014150A2 (en) | 2007-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6685338B2 (en) | Amine cationic lipids and uses thereof | |
US9387262B2 (en) | Coated lipid complexes and their use | |
US20230212578A1 (en) | Compositions and methods for treating hypertriglyceridemia | |
KR102205278B1 (en) | Process for formulating an anionic agent | |
US10945956B2 (en) | Biodegradable compound, lipid particles, composition and kit comprising lipid particles | |
EP2873732A1 (en) | Rnai pharmaceutical composition capable of suppressing expression of kras gene | |
WO2007014150A3 (en) | Method of administering liposomes containing oligonucleotides | |
WO2005067632A3 (en) | Lipid compositions and use thereof | |
AU2008230379B2 (en) | Prompt nucleic acid delivery carrier composition | |
WO2015186770A1 (en) | Ckap5-gene-silencing rnai pharmaceutical composition | |
Wong et al. | A lipid-based delivery system for antisense oligonucleotides derived from a hydrophobic complex | |
US20130090369A1 (en) | Transfection sheets and methods of use | |
PL355231A1 (en) | Cationic dosper virosomes | |
Sternberg et al. | Steric stabilization of cationic liposome-DNA complexes: influence on morphology and transfection activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06788296 Country of ref document: EP Kind code of ref document: A2 |